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Abstract
Detection of Aspergillus IgG antibodies is important in the diagnosis of chronic pulmonary aspergillosis and allergic bronchopulmonary
aspergillosis. Immunoprecipitation techniques to detect these antibodies appear to lack sensitivity and accurate quantitation compared with
enzyme immunoassays (EIA). This study assessed the performance of two commercial EIAs compared with counterimmunoelectrophoresis
(CIE). This was a prospective cohort study of 175 adult patients with chronic or allergic pulmonary aspergillosis. Aspergillus IgG antibodies
were detected using CIE, Phadia ImmunoCap Aspergillus IgG and Bio-Rad Platelia Aspergillus IgG. Inter-assay reproducibility was determined
for each method and 25 patients had two serum samples analysed within a 6-month interval. When compared with CIE, both ImmunoCap
and Platelia Aspergillus IgG had good sensitivity (97 and 93%, respectively) for detection of Aspergillus IgG antibodies. The level of agreement
between the two EIAs for positive results was good, but the concentration of antibodies was not correlated between the tests or with CIE
titre. ImmunoCap IgG inter-assay coefﬁcient of variation was 5%, whereas Platelia IgG was 33%. Median ImmunoCap IgG values for CPA and
allergic aspergillosis were 95 and 32 mg/L, respectively, whereas Platelia IgG values were >80 and 6 AU/mL. The direction of CIE titre
change over 6 months was mirrored by ImmunoCap IgG levels in 92% of patients, and by Platelia IgG in 72% of patients. Both ImmunoCap
and Platelia Aspergillus IgG EIAs are sensitive measures of Aspergillus IgG antibodies compared with CIE. However, ImmunoCap appears to
have better reproducibility and may be more suitable for monitoring patient disease.
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Introduction
Aspergillus is a ubiquitous fungus that causes a large number of
pulmonary and non-pulmonary diseases [1]. Chronic pulmo-
nary aspergillosis (CPA) and allergic bronchopulmonary asper-
gillosis (ABPA) are two of the commonest pulmonary
manifestations in non-immunocompromised patients [2].
Diagnosis of these conditions relies on a number of clinical,
radiological and microbiological parameters. Important to the
diagnosis of CPA and ABPA is the detection of Aspergillus IgG
antibodies [3, 4]. Traditionally, IgG antibodies were measured
using immunoprecipitation techniques (Aspergillus precipitins)
[5, 6]. Counterimmunoelectrophoresis (CIE) largely replaced
immunodiffusion (agar gel double diffusion), as its performance
is comparable, but the time taken to perform this method is
signiﬁcantly less [7]. However, CIE has deﬁnite limitations,
including poor sensitivity, subjective qualitative results and
labour intensity [8]. There has therefore been a drive to
produce commercial enzyme-linked immunosorbant assays
(ELISA) with the potential for full automation and quantitative
results. IgG antibody speciﬁcity in the diagnosis of aspergillosis
has not been addressed with any rigour.
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The National Aspergillosis Centre (NAC) in Manchester
provides long-term management for patients with CPA and
ABPA. Themonitoring ofAspergillus precipitins has beenused for
many years to aid both diagnosis and response to therapy.
However, with emerging resistance to azole therapies it is
becomingmore important tohave technically consistent and fully
quantitative Aspergillus IgG antibody results to guide early
investigation and management [9]. Therefore, this study aimed
tocompare twocommercialAspergillus IgGantibody tests, Phadia
ImmunoCapTM ﬂuorenzymeimmunoassay (FEIA) (Phadia, Upp-
sala, Sweden) and Bio-Rad PlateliaTM Aspergillus IgG EIA (Marnes-
la-Coquette, France), with CIE to detect and monitor Aspergillus
IgG antibodies in patients with chronic and allergic aspergillosis.
Materials and Methods
Patients and sera collection
This was a prospective cohort study. Sera were collected from
175 adult patients attending routine outpatient appointments at
the NAC in Manchester, UK, between February 2010 and
September 2010. Patients were grouped, following serum
collection, according to previously diagnosed disease. One
hundred and sixteen patients had CPA as deﬁned by the criteria
of Denning and colleagues [3], forty-one patients had ABPA as
deﬁned by Greenberger’s criteria [4], ﬁve had severe asthma
with fungal sensitization (SAFS) [10], and 13 patients did not
meet the criteria for any of these conditions (three with fungal
rhinosinusitis, twowith extrinsic allergic alveolitis and eight with
no evidence of fungal disease or sensitization but chronic lung
disease). For data analysis, ABPA and SAFS patients were
grouped together. None of the patients had cystic ﬁbrosis and
any immunosuppression was conﬁned to inhaled and low-dose
oral corticosteroids. None of the patients had received a
transplant or had malignant haematological disease.
IgG levels over 6 months
Serum was collected at two separate appointments within a 6-
month period from 25 patients receiving antifungal therapy, to
observe changing IgG levels over time. The ﬁrst 25 patients to
have a routine repeat blood test within the study period were
selected. No details were collected regarding clinical features
or serum drug levels.
Serolgical analysis
Sera were tested for speciﬁc Aspergillus IgG antibodies by three
separate techniques.
CIE. Aspergillus fumigatus somatic and culture ﬁltrate antigens
were obtained from Microgen Bioproducts (Camberley,
Surrey, UK) at dilutions of 20 and 2 mg/mL. The test was
performed by CIE in an agarose gel and electrophoresed in a
boric acid/EDTA buffer, pH 8.2, for 90 min. Results were
expressed as a titre, based on the highest serum dilution
where a precipitation line was visible. A titre of  1 (neat
serum) was considered positive. For purposes of inter-assay
reproducibility, 40 serum samples were tested twice by
different technicians. Technicians processing these samples
were blinded to the results of other tests or patient details.
ImmunoCap Aspergillus IgG. Speciﬁc A. fumigatus IgG concen-
trations were determined using Gm3 ImmunoCaps on an
ImmunoCap 250 machine. Gm3 ImmunoCaps are derived
from whole extract of Aspergillus conidia and mycelium. Serum
samples were instrument-diluted to 1 in 100 and the
measurement range was 2–200 mg/L. For samples with an
antibody level >200 mg/L, serum was diluted to 1 in 200 and
processed again, results being determined by multiplying the
concentration obtained by 2. A level of >40 mg/L was
considered positive. This is the cut-off level used by UK
laboratories following agreement at a consensus meeting
between six UK laboratories and Phadia, which analysed
unpublished data from eight UK centres. Fifty samples were
processed twice to determine inter-assay reproducibility.
Technicians processing these samples were blinded to the
results of other tests and patient details.
Platelia Aspergillus IgG. The Platelia EIA detects Aspergillus IgG
antibodies against a puriﬁed, unspeciﬁed recombinant antigen.
Serum samples were diluted to 1 in 400 and processed manually
according to themanufacturer’s instructions. Theoptical density
was measured at 450 nm and the IgG concentration was
calculated by drawing a calibration curve from the ﬁve calibra-
tors provided with the assay. The manufacturer recommends a
concentration <5 AU/mL as negative, 5–10 AU/mL as interme-
diate and  10 AU/mL as positive. For samples with a titre of
>80 AU/mL the manufacturer recommends that the sample be
repeated with an additional 1 in 5 dilution if optical density (OD)
<3.0 or 1 in 60 dilution if OD  3.0. Eleven sera were randomly
selected for each dilution, while the remaining results were
expressed as >80 AU/mL without further dilution due to
ﬁnancial constraints. Seventy-eight serum samples were pro-
cessed twice by different operators to determine inter-assay
reproducibility.
Statistical analysis
Statistical analysis was performed using SPSS version 16.0 (SPSS
Inc., Chicago, IL, USA). Correlation of results between tests was
calculated by global agreements and Gwet’s AC1, which gives
more accurate percentages of agreement than Cohen’s Kappa
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coefﬁcient when one agreed category has a small percentage
[11]. Concordance for Gwet’s AC1 is measured on the same
scale as Landis and Koch’s kappa criteria: >0.8 excellent, 0.61–
0.8 substantial, 0.41–0.6moderate, 0.21–0.4 fair, <0.2 poor [12].
Reproducibility of each test was calculated by coefﬁcients of
variation (CVs), Spearman’s correlation coefﬁcient and Bland
Altman plots of agreement between repeated measures.
Concentrations of IgG antibody between disease groups were
compared using Kruskal–Wallis tests and Mann–Whitney U-
tests.
Results
Sera were collected from 175 patients attending the NAC. The
mean age was 62 years (range 20–84) and 54% of patients were
male.
Test performance
Using the predetermined cut-off levels for positive and
negative results, ImmunoCap had a 97% sensitivity and
Platelia 93% sensitivity compared with CIE. However, the
Platelia and ImmunoCap tests produced more positive results
in all disease categories than CIE (Table 1). Comparing
Platelia and Immunocap, 82% of results were in complete
agreement and Gwet’s AC1 was 0.65, indicating substantial
inter-test concordance.
There were 31 discordant results between the Immuno-
Cap and Platelia tests. Sixteen Platelia tests were positive
when ImmunoCap was negative, and 15 Platelia tests were
negative when ImmunoCap was positive (Table S1, Support-
ing Information). The CIE result was in agreement with
ImmunoCap in 71% and with Platelia in 29% of the discordant
group.
Inter-assay reproducibility
Fifty serum samples were run through the ImmunoCap assay
twice. Five patient samples produced a result of >200 mg/L in
both assay runs. The CV was 5% and Spearman’s correlation
coefﬁcient was 0.996. A Bland Altman plot of agreement
showed that the mean difference between the two results was
0.18 mg/L (SD 3.6 mg/L) (Supporting Information Fig. S1).
Seventy-eight serum samples were run through the Platelia
assay twice. Of the 156 results, 53 (34%) were reported to
have a value >80 AU/mL. Fifteen patient samples had a result
>80 AU/mL in both assay runs. This made calculations of
reproducibility more difﬁcult as results had to be rounded to
80 AU/mL, leading to a likely under-estimation of CV and SD.
The CV was therefore calculated at  33% and Spearman’s
correlation coeffcient was 0.634. A Bland Altman plot of
agreement between measures showed the mean difference
between the two results was 7.0 AU/mL (SD  26 AU/
mL). Lastly, 40 serum samples were run through the CIE assay
twice. The CV was 2% and Spearman’s correlation coefﬁcient
was 0.81. The mean difference between the two tests was 0.15
(SD 1.1).
IgG antibody concentrations between tests
The correlation between CIE titre and both the ImmunoCap
and Platelia tests is shown in Fig. 1. There was poor
correlation between both tests and CIE titre (Spearman’s
correlation coefﬁcient ImmunoCap r = 0.54, Platelia r = 0.52).
Sixty-three (36%) of the Platelia samples gave a result
>80 AU/mL necessitating dilution, whereas 15 (9%) of the
ImmunoCap samples required dilution. Twenty-two Platelia
samples were diluted (11 for each of the 1 in 5 and the 1 in 60
dilutions) and 15 ImmunoCap samples. Following dilution, the
mean value for the Platelia results was 586 AU/mL (range
114–1806) and the mean value for the ImmunoCap results
TABLE 1. Aspergillus fumigatus IgG antibody detection rates compared with CIE, according to disease category, for Platelia and
ImmunoCap assays
CIE positive CIE negative CIE positive CIE negative
CPA (n = 116)
Platelia positive 62 37 ImmunoCap positive 63 37
Platelia negative 3 14 ImmunoCap negative 2 14
ABPA (n = 46)
Platelia positive 6 15 ImmunoCap positive 6 13
Platelia negative 1 24 ImmunoCap negative 1 26
Other (n = 13)
Platelia positive 0 2 ImmunoCap positive 1 4
Platelia negative 1 10 ImmunoCap negative 0 8
Disease
Platelia ImmunoCap CIE
Positive (%) Negative (%) Positive (%) Negative (%) Positive (%) Negative (%)
CPA (n = 116) 99 (85) 17 (15) 100 (86) 16 (14) 65 (56) 51 (44)
ABPA/SAFS (n = 46) 21 (46) 25 (54) 19 (41) 27 (59) 7 (15) 39 (85)
Other (n = 13) 2 (13) 11 (87) 5 (38) 8 (62) 1 (8) 12 (92)
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was 623 mg/L (range 200–1641). A comparison between pre-
dilution results for the ImmunoCap and Platelia results is
shown in Fig. 2. Spearman’s correlation coefﬁcient was
r = 0.68, coefﬁcient of determination 46%, but it is clear
from Fig. 2 that there was a very wide range of ImmunoCap
results when Platelia was >80 AU/mL. When negative results
and those beyond the upper limit of the assays were removed
the correlation coefﬁcient was 0.04.
IgG antibody concentrations between disease categories
There was a wide range of values for all tests against each
disease category (Fig. 3). A Kruskal–Wallis test revealed
statistically signiﬁcant differences in Platelia IgG concentrations
between the disease categories (v2 (d.f. 2, n = 175) = 56,
p <0.001). Median values for each group were: CPA > 80 AU/
mL, ABPA 6 AU/mL, ‘Other’ 0.3 AU/mL. Post-hoc Mann–
Whitney U-tests with Bonferroni correction of calculated
p-values showed that patients with CPA had statistically higher
IgG concentrations than those with ABPA/SAFS (p <0.001) or
those with other diseases (p <0.001). There was no signiﬁcant
difference between ABPA/SAFS patients and patients with
‘Other’ diseases (p 0.08). For ImmunoCap IgG concentrations
the Kruskal–Wallis test again revealed statistically signiﬁcant
differences in IgG concentrations between the disease cate-
gories (v2 (d.f. 2, n = 175) = 38, p <0.001). Median values for
each group were: CPA 95 mg/L, ABPA/SAFS 32 mg/L, ‘Other’
36 mg/L. Post-hoc tests showed similar results to the Platelia
test, with CPA patients having statistically higher IgG concen-
trations than ABPA/SAFS patients (p <0.001) and ‘Other’
diseases (p 0.003) but no signiﬁcant difference between ABPA/
SAFS and ‘Other’ diseases (p 0.70). CIE titres were in
agreement with these ﬁndings.
IgG levels over 6 months
Twenty-ﬁve patients had two blood samples taken within a 6-
month interval. Each sample was tested for Aspergillus IgG
antibodies by the three tests under investigation (Table 2).
Signiﬁcant changes were deﬁned as a change of >2 SD of the
mean as per earlier measures of reproducibility. Seven patients
had Platelia IgG levels >80 on both occasions. One of these
had ImmunoCap concentrations >200 mg/L, four had a fall in
ImmunoCap IgG and two had a rise in ImmunoCap IgG. These
changes were mirrored by the same directional change in CIE
titres. Ten patients demonstrated the same directional change
in results between all three tests. The remaining eight patients
had discordant results for the three tests. Overall, excluding
those with results above the assay limit of detection,
FIG. 1. Correlation between ImmunoCap and Platelia Aspergillus IgG
levels and precipitin (CIE) titre. There was one precipitin titre of 32,
which has not been included in the ﬁgures due to scale: the
ImmunoCap IgG level was 76 mg/L while the Platelia IgG was
>80 AU/mL.
FIG. 2. Correlation between ImmunoCap and Platelia Aspergillus IgG
concentrations. All 15 ImmunoCap results with a titre of >200 mg/L
had a Platelia IgG concentration >80 AU/mL. For Platelia results
>80 AU/mL there was a wide variation of ImmunoCap results (45–
200 mg/L).
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ImmunoCap mirrored CIE change in 22 (92%) of 24 patients,
and Platelia in 14 (78%) of 18 patients.
Discussion
This study has evaluated the performance of two commercial
EIAs used to detect and monitor Aspergillus IgG precipitating
antibodies and compared it with CIE in patients with chronic
and allergic aspergillosis. Both assays had good sensitivity when
compared with CIE. In fact, sensitivity appeared to be
signiﬁcantly better than that of CIE, with ImmunoCap and
Platelia tests detecting Aspergillus IgG antibodies in 29–30%
more CPA patients and in 26–31% more ABPA/SAFS patients.
The actual sensitivity of these assays to detect disease cannot
be determined from this data as many patients were already on
FIG. 3. Distribution of Aspergillus IgG concentrations in each patient group. Where the number of patients with a particular IgG concentration is
indistinct, these have been labelled.
TABLE 2. Aspergillus IgG concen-
trations from two blood samples
taken within 6 months
Patient
Platelia IgG (AU/mL)
ImmunoCap IgG (mg/
L) CIE (titre)
Test 1 Test 2 Test 1 Test 2 Test 1 Test 2
1 >80 >80 >200 >200 1 2
2 >80 >80 >200 133 8 2
3 >80 >80 190 173 8 2
4 >80 >80 107 62 8 0
5 >80 >80 >200 148 8 1
6 >80 >80 183 195 2 4
7 >80 >80 97 114 0 1
8 17 >80 13 49 0 2
9 75 >80 135 146 4 8
10 34 51 55 56 1 1
11 41 38 100 95 1 1
12 >80 69 78 58 1 0
13 10 5 19 15 0 0
14 0 0 15 13 0 0
15 0 0 12 9 0 0
16 0 1 11 10 0 0
17 4 0 33 28 0 0
18 13 16 29 27 0 0
19 56 27 44 46 0 0
20 27 55 49 89 0 1
21 10 21 86 121 2 4
22 38 >80 85 85 1 1
23 8 67 81 60 1 0
24 45 63 101 78 0 0
25 1 1 108 91 0 0
Signiﬁcant changes in results are deﬁned as a change in value >2 SD of the mean from reproducibility tests: Platelia
52 AU/mL and ImmunoCap 8 mg/L.
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antifungal medication at the time of serum collection and there
was no control group. However, it is noteworthy that the
eight patients with no evidence of fungal disease were negative
on both assays. The ImmunoCap and Platelia IgG tests showed
good levels of agreement (82%) and inter-rater reliability
(Gwet’s AC1 0.65). For discordant results there was an equal
mix of positive Platelia and positive ImmunoCap results, but
CIE results agreed with ImmunoCap in 72% of cases but only
29% of Platelia IgG results. However, the Platelia IgG test
detected 14 positive results in the CPA/ABPA groups and two
in the ‘Other’ group, whereas ImmunoCap detected 11
positive results in the CPA/ABPA groups and four in the
‘Other’ group. Interpreting this in the context of sensitivity and
speciﬁcity for disease identiﬁcation is not possible due to the
lack of a control group and concurrent antifungal treatment for
those with CPA/ABPA.
There was a signiﬁcant difference between the performance
of the ImmunoCap and Platelia assays during tests of inter-
assay reproducibility. The Platelia IgG assay was more difﬁcult
to analyse due to a large number of results with a value
>80 AU/mL. The Platelia IgG assay was run on 78 samples
twice by different operators and the CV was  33% with mean
differences of 7 AU/mL and a wide standard deviation of
 26 AU/mL. With a cut-off value of 5 AU/mL this could
seriously affect disease monitoring. The inter-assay CV
reported by the manufacturer is up to 16.2% (product insert),
which is likely to still be signiﬁcant in the context of disease
monitoring. A limitation of our study is that sera were not
tested on the same day, although sera were stored at 80°C
between testing, and furthermore, tests were carried out
manually, introducing potential operator error. We found that
the ImmunoCap assay had a much better inter-assay CV of 5%
and mean differences of <1 mg/L, which would be very unlikely
to affect disease monitoring. We did not analyse intra-assay
reproducibility for either test but Guitard et al. [13] recently
reported the intra-assay precision of the Platelia Aspergillus IgG
assay to be CV 5%, using four sera repeated over 15 runs on
an automated machine. This is similar to the manufacturer data
of up to 3.6% (product insert).
A further drawback of the Platelia Aspergillus IgG test is that,
in this group of patients, 36% (63) of results were above the
upper limit of detection (>80 AU/mL). While this may not be
important for disease detection, it is important for disease
monitoring. To obtain an accurate level with which to monitor
treatment, the assay has to be re-run after additional dilution,
causing considerable expense and laboratory time. This study
was unable to analyse all samples >80 AU/mL due to cost
implications. There was a wide distribution of ImmunoCap
results for these samples (45 to >200 mg/L). Only 15
ImmunoCap IgG results had concentrations >200 mg/L, all of
which had Platelia IgG levels >80 AU/mL. The Platelia IgG test
takes over 3 h to perform and is very labour intensive if not
using automated equipment. Automated ELISA equipment is
currently not standard in UK hospital laboratories. Immuno-
Cap IgG is fully automated and run on the same machine as
other common tests of allergy, to which most UK hospitals
have access.
The correlation of concentrations of IgG antibodies between
the two tests was poor, which may in part reﬂect the poor
reproducibility of the Platelia IgG test or may be explained in
part by the use of different Aspergillus antigens. The ImmunoCap
assay is directed against whole extracts of A. fumigatus conidia
and mycelium containing a wide variety of allergens, whereas
the Platelia assay uses an unspeciﬁed puriﬁed recombinant
Aspergillus antigen (product insert), and detects species other
than A. fumigatus. This is of great importance when trying to
compare sensitivities and IgG concentrations.
Monitoring of Aspergillus IgG antibody levels in 25 patients
over 6 months was performed well by the ImmunoCap assay
compared with CIE titre. Twenty-two (92%) of the 24 results
showed the same directional change or stability as the CIE titre
(one excluded as results above assay limit of detection). The
Platelia IgG test was more difﬁcult to analyse as the poor
reproducibility has an impact on analysis, but if the seven
patients with results >80 AU/mL are excluded, 14 (78%) of 18
patients showed the same directional change as CIE titre.
All three tests showed statistically higher IgG concentra-
tions in those with CPA than ABPA. Up to 59% of ABPA/SAFS
patients were negative for Aspergillus IgG antibodies. However,
many patients were on antifungal treatment and IgG concen-
trations may fall quicker in ABPA compared with CPA, where
the aim of therapy is not cure but control of disease and
prevention of progression. There is currently no deﬁned cut-
off level for either assay in speciﬁc disease groups. One study
suggested an ImmunoCap cut-off of 90 mg/L for diagnosis of
ABPA in cystic ﬁbrosis with a sensitivity of 91% and speciﬁcity
of 88% [14]. A further study reported an ImmunoCap cut-off
of 70 mg/L as giving a sensitivity of 70% in patients with
invasive aspergillosis/ABPA and 98% speciﬁcity in healthy
controls [15]. The Platelia Aspergillus IgG test has been
evaluated in the diagnosis of non-invasive aspergillosis in one
retrospective study, which found good sensitivity (90–94%) for
patients with CPA and ABPA and a speciﬁcity of 99% using
control sera from healthy pregnant women [13].
A limitation of this study is the lack of documented clinical
features and details of concurrent antifungal treatment, which
may have provided more precise interpretation of results,
particularly for patients in whom more than one serum sample
was tested over time. An area not properly explored by this or
any study of Aspergillus IgG serology is that of speciﬁcity. Blood
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 19, E197–E204
E202 Clinical Microbiology and Infection, Volume 19 Number 4, April 2013 CMI
donors or other healthy controls provide a baseline ﬁgure, but
are not useful in the context of a respiratory service where
consideration of some form of aspergillosis is present in the vast
majority of patients. In a sense then, only matched patients can
be used to determine speciﬁcity, but in this case invasive,
chronic and allergic aspergillosis, as well as Aspergillus bronchitis
[16], need to be excluded. In a separate study, in cystic ﬁbrosis
patients, we have addressed this by prospective recruitment,
testing all patients with the same protocol, latent class analysis,
to deﬁne discrete patient groups, and then performing ROC
analysis on the relevant tests within each patient grouping [17].
To truly establish the speciﬁcity of Aspergillus IgG for CPA and
ABPA, this should be done with matching controls, which is
easier for ABPA (asthma) than for CPA (multiple underlying
conditions). Exclusion of Aspergillus disease to establish a true
negative population is now easier with Aspergillus PCR on
sputum, which is far more sensitive than culture [18,19].
Therefore, this study cannot deﬁnitively determine the perfor-
mance of any of the assays for CPA and ABPA, but points the
way towards assay selection for such a study, and addresses
dilution considerations and issues of reproducibility.
In summary, both the ImmunoCap and Platelia Aspergillus
IgG EIAs are sensitive assays for detecting Aspergillus IgG
antibodies. However, the ImmunoCap appears to have better
inter-assay reproducibility, making it more suitable for mon-
itoring patient disease in a routine service setting. Sensitive
assays are required for the diagnosis of CPA as radiology is
often not speciﬁc and cultures are insensitive.
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